Arthneeti
All Q2 FY26 results →
SP

STERIS plc

Q2 FY26Health Care Equipment and Supplies

STERIS plc Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹215
Market cap₹21.1K Cr
P/E27.2
Updated29 May 2026
Read4 min read

What the Q2 FY26 call signalled

2 of 4 strong

RevenueSlow growth
MarginMargins slightly up
CapexCapex planned
Order bookOrder book flat

The short version

- Fiscal 2027 as-reported revenue expected to grow 7% to 8%. - Constant currency organic revenue growth anticipated at 6% to 7% for the total company. - Segment growth outlook: - Healthcare and Life Sciences: 6% to 7% constant currency organic growth. - Advanced Sterilization Products (AST): 7% to 8% growth, starting more conservatively. - U.S. - Fiscal 2027 earnings per share (EPS) outlook: $11.10 to $11.30, reflecting 9% to 11% growth over fiscal 2026.

From STERIS plc's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth
  • Fiscal 2027 as-reported revenue expected to grow 7% to 8%.
  • Constant currency organic revenue growth anticipated at 6% to 7% for the total company.
  • Segment growth outlook:
  • Healthcare and Life Sciences: 6% to 7% constant currency organic growth.
  • Advanced Sterilization Products (AST): 7% to 8% growth, starting more conservatively.
  • U.S. procedure volume expected to grow mid-single digits consistently in fiscal 2027.
  • Inventory levels managed carefully by med tech customers, causing cautious outlook for AST early in the year.
  • Procedure rates and patient demand remain consistent, supporting volume growth.

2 more points from STERIS plc's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what STERIS plc said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Fiscal 2027 CapEx planned at $375 million.
  • New sterility assurance manufacturing plant to be built in Mentor, Ohio.
  • Investment of about $60 million over 2 years.
  • Facility expected operational by end of calendar 2027.
  • Will consolidate existing U.S. production into a state-of-the-art manufacturing center of excellence.
  • Continued investment in AST expansion projects, particularly for x-ray globally.
  • Multiyear project kickoff to support service workflows with upgraded AI technologies aimed at improving quality, productivity, and customer experience in Healthcare and Life Sciences segments.

2 more points from STERIS plc's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what STERIS plc said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book flat
  • Capital equipment backlog ended solidly at just under $100 million (Page 3).
  • Healthcare capital equipment backlog ended just under $400 million with orders up 2% in Q4 (Page 3).
  • Orders have remained solid going forward despite pressures on healthcare systems (Page 7).

Continue your research

Others in Health Care Equipment and Supplies this season

  • Insulet Corporation (Q2 FY26)

    Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24

  • Globus Medical, Inc. (Q2 FY26)

    Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.

  • Align Technology, Inc. (Q2 FY26)

    Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap

  • Solventum Corporation (Q2 FY26)

    Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag

Compare:vs Intuitive Surgical, Inc.vs Stryker Corporationvs Medtronic plc

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

STERIS plc and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were STERIS plc Q2 FY26 results?

- Fiscal 2027 as-reported revenue expected to grow 7% to 8%. - Constant currency organic revenue growth anticipated at 6% to 7% for the total company. - Segment growth outlook: - Healthcare and Life Sciences: 6% to 7% constant currency organic growth. - Advanced Sterilization Products (AST): 7% to 8% growth, starting more conservatively. - U.S. - Fiscal 2027 earnings per share (EPS) outlook: $11.10 to $11.30, reflecting 9% to 11% growth over fiscal 2026.

What is STERIS plc share price analysis?

STERIS plc currently shows a neutral. The stock trades at a P/E of 27.2 with a market cap of $21,125. Investors should review the full earnings analysis for detailed insights.

Is STERIS plc planning capital expenditure?

- Fiscal 2027 CapEx planned at $375 million. - New sterility assurance manufacturing plant to be built in Mentor, Ohio. - Investment of about $60 million over 2 years. - Facility expected operational by end of calendar 2027. - Will consolidate existing U.S.

Keep STERIS plc on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.